Dr. Lorraine Fitzpatrick is the new CMO at Radius Health, a biopharmaceutical company developing therapeutics for patients with advanced osteoporosis and other serious endocrine-mediated diseases.
Fitzpatrick, 61, joined the company on Monday after serving as an international development leader for the bone-building drug Denosumab at U.K.-based drugmaker GlaxoSmithKline.
Before working on Denosumab, Dr. Fitzpatrick led the clinical development of novel agents to treat musculoskeletal diseases and women's health at GSK. Before that, she was an executive director at major biologic drugmaker Amgen, focusing on osteoporosis and oncology.
During her career as a practitioner, Fitzpatrick was chief of endocrine at the Audie Murphy Memorial VA Hospital in San Antonio and assistant professor of medicine at the University of Texas Health Science Center, also in San Antonio. She later worked at the Mayo Clinic as director of bone histomorphometry and as a director of its Women's Health Fellowship, which she founded.
